{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:19:08Z","timestamp":1792293548155,"version":"4.4.0"},"reference-count":20,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Peptide receptor radionuclide therapy (PRRT) is used to treat patients with advanced malignant pheochromocytomas (PCCs) and paragangliomas (PGLs). Patients are at risk of a PRRT-induced catecholamine crisis, and standard guidelines regarding the prevention and management of infusion reactions are lacking. In this case series, the institutional experience of five sequential patients with metastatic PCCs and PGLs receiving PRRT on an outpatient basis is described, of which four had symptomatic tumors and three had a high burden of disease. All patients with symptomatic tumors were treated with preventive management prior to the initiation of PRRT, and no infusion reactions or catecholamine crises were documented. PRRT may be delivered safely on an outpatient basis for patients with metastatic PCCs and PGLs with the involvement of an interdisciplinary team.<\/jats:p>","DOI":"10.3390\/curroncol28040247","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T04:19:30Z","timestamp":1627273170000},"page":"2823-2829","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT"],"prefix":"10.3390","volume":"28","author":[{"given":"Erica S.","family":"Tsang","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, BC Cancer, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayle","family":"Funk","sequence":"additional","affiliation":[{"name":"Virginia Mason Cancer Institute, Seattle, WA 98101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Leung","sequence":"additional","affiliation":[{"name":"Virginia Mason Cancer Institute, Seattle, WA 98101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kalish","sequence":"additional","affiliation":[{"name":"Virginia Mason Cancer Institute, Seattle, WA 98101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen F.","family":"Kennecke","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute & Chiles Research Institute, Portland, OR 97213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/eci.12495","article-title":"Metastatic pheochromocytoma and paraganglioma","volume":"45","author":"Angelousi","year":"2015","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"National Comprehensive Cancer Network (2019). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Thorac. Surg. Clin., 25, 185\u2013197.","DOI":"10.1016\/j.thorsurg.2014.12.003"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Chougnet","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","article-title":"Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma","volume":"57","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: Systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: The SNIPP trial","volume":"120","author":"Ezzat","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-017-0643-0","article-title":"Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress","volume":"19","author":"Jimenez","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"NETTER-1 Trial Investigators: Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s13139-018-0517-x","article-title":"Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives","volume":"52","author":"Hirmas","year":"2018","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jso.24553","article-title":"Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas","volume":"115","author":"Nastos","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12032-016-0737-9","article-title":"Peptide receptor radionuclide therapy for metastatic paragangliomas","volume":"33","author":"Pinato","year":"2016","journal-title":"Med. Oncol."},{"key":"ref_14","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and\/or Unresectable Pheochromocytoma and Paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00259-007-0691-z","article-title":"Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate","volume":"35","author":"Feelders","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13139-015-0332-6","article-title":"The Challenges of Treating Paraganglioma Patients with (177)Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols","volume":"49","author":"Makis","year":"2015","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000475526","article-title":"Antibes Consensus Conference participants: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000499497","article-title":"Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma","volume":"109","author":"Mak","year":"2019","journal-title":"Neuroendocrinology"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/4\/247\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:34:49Z","timestamp":1760164489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/4\/247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["curroncol28040247"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28040247","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]}}}